Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Intangibles (2018 - 2025)

Historic Intangibles for Autolus Therapeutics (AUTL) over the last 7 years, with Q3 2025 value amounting to $20.3 million.

  • Autolus Therapeutics' Intangibles changed N/A to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year change of. This contributed to the annual value of $12.4 million for FY2024, which is N/A changed from last year.
  • Autolus Therapeutics' Intangibles amounted to $20.3 million in Q3 2025.
  • Autolus Therapeutics' Intangibles' 5-year high stood at $20.3 million during Q3 2025, with a 5-year trough of $8000.0 in Q3 2022.
  • Over the past 4 years, Autolus Therapeutics' median Intangibles value was $112000.0 (recorded in 2021), while the average stood at $5.3 million.
  • In the last 5 years, Autolus Therapeutics' Intangibles tumbled by 3691.59% in 2021 and then tumbled by 9080.46% in 2022.
  • Autolus Therapeutics' Intangibles (Quarter) stood at $65000.0 in 2021, then plummeted by 87.69% to $8000.0 in 2022, then skyrocketed by 154562.5% to $12.4 million in 2024, then surged by 63.93% to $20.3 million in 2025.
  • Its Intangibles was $20.3 million in Q3 2025, compared to $12.9 million in Q2 2025 and $12.5 million in Q1 2025.